H.C. Wainwright views the results of CymaBay Therapeutics’s RESPONSE Phase 3 trial of seladelpar in patients with primary biliary cholangitis as “positive all-around.” The registration trial achieved the primary and all key secondary endpoints and supports advancement to regulatory discussions and filing for regulatory approval in the U.S., the U.K. and the European Union, the analyst tells investors in a research note. The firm is “very pleased with the strong results all-around,” all of which it says are highly statistically significant. It keeps a Buy rating on CymaBay with a $21 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay (NASDAQ:CBAY) Rises on Promising Phase 3 Results in Liver Disease
- CymaBay announces Phase 3 RESPONSE study achieved primary endpoint
- CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 8/15/2023, According to Top Analysts